Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial

Lauren Carcas; C H Barcenas; Philip Hurvitz; J A Di Palma; R Bose; A J Chien; N Iannotti; G Marx; A Brufsky; A Litvak; E Ibrahim; R H Alvarez; M Ruiz-Borrego; N Chan; Y Manalo; Andrea Kellum; M Trudeau; M Thirlwell; J Garcia Saenz; D Hunt; R Bryce; L McCulloch; H S Rugo; D Tripathy; A Chan; CONTROL Study Investigators

doi:10.1016/j.annonc.2020.05.012

Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial

Lauren Carcas, C H Barcenas, Philip Hurvitz, J A Di Palma, R Bose, A J Chien, N Iannotti, G Marx, A Brufsky, A Litvak, E Ibrahim, R H Alvarez, M Ruiz-Borrego, N Chan, Y Manalo, Andrea Kellum, M Trudeau, M Thirlwell, J Garcia Saenz, D HuntR Bryce, L McCulloch, H S Rugo, D Tripathy, A Chan, CONTROL Study Investigators

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	31
DOIs	https://doi.org/10.1016/j.annonc.2020.05.012
State	Published - Sep 2020

Disciplines

Medicine and Health Sciences

Access to Document

10.1016/j.annonc.2020.05.012License: Unspecified

Cite this

Carcas, L., Barcenas, C. H., Hurvitz, P., Di Palma, J. A., Bose, R., Chien, A. J., Iannotti, N., Marx, G., Brufsky, A., Litvak, A., Ibrahim, E., Alvarez, R. H., Ruiz-Borrego, M., Chan, N., Manalo, Y., Kellum, A., Trudeau, M., Thirlwell, M., Garcia Saenz, J., ... Study Investigators, CONTROL. (2020). Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial. Annals of Oncology, 31. https://doi.org/10.1016/j.annonc.2020.05.012

Carcas, L, Barcenas, CH, Hurvitz, P, Di Palma, JA, Bose, R, Chien, AJ, Iannotti, N, Marx, G, Brufsky, A, Litvak, A, Ibrahim, E, Alvarez, RH, Ruiz-Borrego, M, Chan, N, Manalo, Y, Kellum, A, Trudeau, M, Thirlwell, M, Garcia Saenz, J, Hunt, D, Bryce, R, McCulloch, L, Rugo, HS, Tripathy, D, Chan, A & Study Investigators, CONTROL 2020, 'Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial', Annals of Oncology, vol. 31. https://doi.org/10.1016/j.annonc.2020.05.012

@article{0fec6b6cfdf241f6b470e0bdb71d5ab9,

title = "Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial",

author = "Lauren Carcas and Barcenas, \{C H\} and Philip Hurvitz and \{Di Palma\}, \{J A\} and R Bose and Chien, \{A J\} and N Iannotti and G Marx and A Brufsky and A Litvak and E Ibrahim and Alvarez, \{R H\} and M Ruiz-Borrego and N Chan and Y Manalo and Andrea Kellum and M Trudeau and M Thirlwell and \{Garcia Saenz\}, J and D Hunt and R Bryce and L McCulloch and Rugo, \{H S\} and D Tripathy and A Chan and \{Study Investigators\}, CONTROL",

note = "Title Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial Additional Authors: Additional authors and institutional affiliations Citation Carcas, Lauren, {"}Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial{"} (2020). All Publications. 4444. https://scholarlycommons.baptisthealth.net/se-all-publications/4444",

year = "2020",

month = sep,

doi = "10.1016/j.annonc.2020.05.012",

language = "American English",

volume = "31",

journal = "Annals of Oncology",

}

TY - JOUR

T1 - Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial

AU - Carcas, Lauren

AU - Barcenas, C H

AU - Hurvitz, Philip

AU - Di Palma, J A

AU - Bose, R

AU - Chien, A J

AU - Iannotti, N

AU - Marx, G

AU - Brufsky, A

AU - Litvak, A

AU - Ibrahim, E

AU - Alvarez, R H

AU - Ruiz-Borrego, M

AU - Chan, N

AU - Manalo, Y

AU - Kellum, Andrea

AU - Trudeau, M

AU - Thirlwell, M

AU - Garcia Saenz, J

AU - Hunt, D

AU - Bryce, R

AU - McCulloch, L

AU - Rugo, H S

AU - Tripathy, D

AU - Chan, A

AU - Study Investigators, CONTROL

N1 - Title Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial Additional Authors: Additional authors and institutional affiliations Citation Carcas, Lauren, "Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial" (2020). All Publications. 4444. https://scholarlycommons.baptisthealth.net/se-all-publications/4444

PY - 2020/9

Y1 - 2020/9

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4444/

U2 - 10.1016/j.annonc.2020.05.012

DO - 10.1016/j.annonc.2020.05.012

M3 - Article

VL - 31

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Improved Tolerability of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer: the CONTROL Trial

Disciplines

Access to Document

Other files and links

Cite this